Minerva Neurosciences, Inc (NASDAQ:NERV) – Research analysts at Jefferies Group dropped their FY2017 EPS estimates for Minerva Neurosciences in a report issued on Monday. Jefferies Group analyst B. Amin now forecasts that the biopharmaceutical company will post earnings of ($1.28) per share for the year, down from their previous estimate of ($1.26). Jefferies Group also issued estimates for Minerva Neurosciences’ Q4 2017 earnings at ($0.43) EPS, FY2018 earnings at ($1.50) EPS, FY2019 earnings at ($1.53) EPS, FY2020 earnings at ($1.74) EPS and FY2021 earnings at ($1.35) EPS.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter. During the same quarter in the prior year, the firm earned ($0.24) EPS.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/11/10/fy2017-earnings-forecast-for-minerva-neurosciences-inc-issued-by-jefferies-group-nerv.html.

Several other equities analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research note on Thursday, October 5th. Citigroup Inc. assumed coverage on shares of Minerva Neurosciences in a research note on Friday, September 1st. They set a “buy” rating and a $11.00 target price for the company. Finally, BidaskClub cut shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Minerva Neurosciences has a consensus rating of “Hold” and an average price target of $13.94.

Minerva Neurosciences (NERV) opened at $5.00 on Wednesday. Minerva Neurosciences has a 52 week low of $4.95 and a 52 week high of $14.15.

Several large investors have recently modified their holdings of the business. Trexquant Investment LP purchased a new position in shares of Minerva Neurosciences in the 3rd quarter worth $189,000. JPMorgan Chase & Co. purchased a new position in shares of Minerva Neurosciences in the 3rd quarter worth $2,835,000. Sphera Funds Management LTD. grew its stake in shares of Minerva Neurosciences by 31.9% in the 3rd quarter. Sphera Funds Management LTD. now owns 625,000 shares of the biopharmaceutical company’s stock worth $4,750,000 after buying an additional 151,231 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Minerva Neurosciences by 33.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 121,152 shares of the biopharmaceutical company’s stock worth $921,000 after buying an additional 30,223 shares in the last quarter. Finally, Alps Advisors Inc. grew its stake in shares of Minerva Neurosciences by 26.4% in the 3rd quarter. Alps Advisors Inc. now owns 41,864 shares of the biopharmaceutical company’s stock worth $318,000 after buying an additional 8,733 shares in the last quarter. 69.75% of the stock is owned by institutional investors and hedge funds.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Receive News & Stock Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related stocks with our FREE daily email newsletter.